Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

NSCLC 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 34Pemetrexed 27Drug Therapy 22Cisplatin 22osimertinib 19aflutinib 11Paclitaxel 11pembrolizumab 10Surgical Procedures, Operative 10Docetaxel 10tislelizumab 9Radiotherapy 8Magnetic Resonance Spectroscopy 8anlotinib 7Specimen Handling 7Bevacizumab 7130-nm albumin-bound paclitaxel 7toripalimab 6cemiplimab 6Immunotherapy 6sintilimab 5ensartinib 5durvalumab 5Radiosurgery 5Platinum Compounds 5Nivolumab 5trametinib 4aumolertinib 4Observation 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Non-Small-Cell Lung × Diphenhydramine × Clear all
NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
430 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡